Clinical Trial

QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants. Secondary Objectives: To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT, RR, PR and QRS intervals) in healthy Chinese participants; To verify assay sensitivity by evaluating the effect of moxifloxacin on QTcF interval; To evaluate the safety and tolerability of single-dose TQ05105 in healthy Chinese participants; To characterize the pharmacokinetic (PK) characteristics of TQ05105 and its metabolite (TQ12550) after single administration of TQ05105 tablets in healthy Chinese participants.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-08-08
Trial Details
NCT Number NCT07708272
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Myelofibrosis
Enrollment 60 participants
Start Date 2026-07-30
Primary Completion 2026-12 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-07